share_log

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for Pegunigalsidase Alfa

PR Newswire ·  Dec 9 19:30
(PRNewsfoto/Chiesi Global Rare Diseases)
Protalix BioTherapeutics, Inc. (PRNewsfoto/Protalix BioTherapeutics, Inc.,Chiesi Global Rare Diseases)
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment